6-K 1 f6k_011215.htm FORM 6-K f6k_011215.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
________________
 
FORM 6-K
________________
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
January 12, 2015
________________
 
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
 
 
Novo Allé 
DK- 2880, Bagsvaerd 
Denmark
(Address of principal executive offices)
________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
 
Form 20-F [X]     
     Form 40-F [  ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes [  ]     
      No [X]
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
 
 
 
Novo Nordisk A/S – Share repurchase programme
 

Bagsværd, Denmark, 12 January 2015 – On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
 
Under the programme initiated 30 October 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 30 October 2014 to 28 January 2015.
 
Since the announcement as of 22 December 2014, the following transactions have been made under the programme:
 
 
 
Number of
B shares
 
 
Average
purchase price
 
Transaction
value, DKK
Accumulated, last announcement
9,323,000
 
2,499,721,508
2 January 2015
260,000
263.43
68,492,528
5 January 2015
240,000
265.66
63,759,216
6 January 2015
240,000
264.10
63,383,760
7 January 2015
285,000
265.46
75,655,587
8 January 2015
210,000
268.63
56,412,426
9 January 2015
275,000
271.13
74,561,108
       
Accumulated under the programme
10,833,000
 
2,901,986,132
 
 
With the transactions stated above, Novo Nordisk owns a total of 58,317,153 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.
 
 
 

 
Page 2 of 2
 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 9 January 2015, Novo Nordisk has repurchased a total of 55,856,995 B shares equal to a transaction value of DKK 14,106,361,348.
 
 
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
 
 
 
Further information
   
Media:
   
Anne Margrethe Hauge
+45 3079 3450
amhg@novonordisk.com
     
Investors:    
Kasper Roseeuw Poulsen
+45 3079 4303
krop@novonordisk.com
Jannick Lindegaard Denholt
+45 3079 8519
jlis@novonordisk.com
Daniel Bohsen
+45 3079 6376
dabo@novonordisk.com
Melanie Raouzeos
+45 3075 3479
mrz@novonordisk.com
Frank Daniel Mersebach (US)
+1 609 235 8567
fdni@novonordisk.com

 
 
 
 
 
 
 
Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
 
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
       
   
Company announcement No 2 / 2015
 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
 
Date: January 12, 2015
 
NOVO NORDISK A/S
 
Lars Rebien Sørensen,
Chief Executive Officer